Last edition
News about "Denosumab biosimilars"
Biocon Biologics, Amgen Settle Patent Dispute, Paving Way for US Launch of Denosumab Biosimilars
The agreement with Amgen enables Biocon Biologics to launch denosumab biosimilars Bosaya and Aukelso in the US from October 1, 2025.
Denosumab Biosimilars | 01/10/2025 | By Dineshwori | 239
Biocon Biologics Secures US FDA Approval for Denosumab Biosimilars Bosaya and Aukelso
The US Food and Drug Administration (FDA) has approved Biocon Biologics' denosumab biosimilars, Bosaya (denosumab-kyqq) 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection in a single-dose vial, biosimilars of Prolia and Xgeva, respectively.
Denosumab Biosimilars | 17/09/2025 | By Dineshwori | 346
Biocon Biologics Receives European Commission Nod for Denosumab Biosimilars to Improve Bone Health
Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo and Evfraxy, thereby expanding access to advanced treatments for bone-related conditions across the EU.
Denosumab Biosimilars | 03/07/2025 | By Mrinmoy Dey | 155
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy